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Smoking increases the risk of venous thrombosis and acts
synergistically with oral contraceptive use
Elisabeth R. Pomp,1 Frits R. Rosendaal,1,2,3* and Carine J.M. Doggen1
The results of studies investigating the relationship of smoking with venous thrombosis are inconsistent.
Therefore, in the MEGA study, a large population-based case–control study, we evaluated smoking as a risk
factor for venous thrombosis and the joint effect with oral contraceptive use and the factor V Leiden muta-
tion. Consecutive patients with a first venous thrombosis were included from six anticoagulation clinics.
Partners of patients were asked to participate and additional controls were recruited using a random digit
dialing method. Participants completed a standardized questionnaire. Individuals with known malignancies
were excluded from the analyses, leaving a total of 3,989 patients and 4,900 controls. Current and former
smoking resulted in a moderately increased risk of venous thrombosis (odds ratio (OR)current 1.43, 95%
confidence interval (CI95) 1.28–1.60, ORformer 1.23, CI95 1.09–1.38) compared with nonsmoking. Adjustment
for fibrinogen levels did not substantially change these risk estimates. A high number of pack-years
resulted in the highest risk among young current smokers (OR20 pack-years 4.30, CI95 2.59–7.14) compared
with young nonsmokers. Women who were current smokers and used oral contraceptives had an 8.8-fold
higher risk (OR 8.79, CI95 5.73–13.49) than nonsmoking women who did not use oral contraceptives. Rela-
tive to nonsmoking noncarriers, the joint effect of factor V Leiden and current smoking led to a 5.0-fold
increased risk; for the prothrombin 20210A mutation this was a 6.0-fold increased risk. In conclusion, smok-
ing appears to be a risk factor for venous thrombosis with the greatest relative effect among young women
using oral contraceptives. Am. J. Hematol. 83:97–102, 2008. VC 2007 Wiley-Liss, Inc.
Introduction
Venous thrombosis is a common and serious disorder
with acquired and genetic risk factors [1]. Several of these
risk factors are common for arterial and venous thrombosis,
e.g., oral contraceptive use [2]. Factors that promote ather-
osclerosis are thought not to have an effect on venous
thrombosis. Smoking is directly related to vessel-wall dam-
age [3], but may also increase the risk of cardiovascular
disease through other mechanisms, such as inflammation
and increased fibrinogen levels [4-9]. These may lead to ar-
terial as well as venous thrombotic disease. Results of
studies investigating the relationship between smoking and
venous thrombosis are inconsistent and vary from an
adverse to a protective effect of smoking. In the ‘‘The
Nurses Health Study’’ a twofold increased risk of pulmonary
embolism was reported in women who smoked more than
35 cigarettes per day compared with never smokers [10].
‘‘The Study of Men born in 1913’’ reported a threefold
increased risk of venous thrombotic events in men smoking
more than 15 cigarettes per day [11]. In contrast, The Fra-
mingham study showed that cigarette use had no associa-
tion with pulmonary embolism found at autopsy [12]. A fol-
low-up study of middle-aged and elderly individuals also
found no effect of smoking on venous thrombosis [13]. In a
case–control study from France regular smoking was pro-
tective for deep venous thrombosis of the leg [14]. This
finding may be explained by the nature of the control group
that consisted of individuals with influenzal or rhinopharyng-
eal syndrome, i.e., which may have had an excess of
smokers. The reason for the discrepancy between the other
study results is unclear.
A risk-increasing effect of smoking may be mediated
through an increase in coagulation factors [8]. It is well
known that smokers have higher fibrinogen levels [5-9] and
that smoking cessation causes a rapid fall in plasma fibri-
nogen [6]. Elevated levels of fibrinogen were related to the
risk of venous thrombosis in the ‘‘The Leiden Trombophilia
Study’’ (LETS), where we reported a 2.8-fold increased risk
for individuals with fibrinogen levels above the 95th percen-
tile (4.49 g/L) [15]. A case–control study among African-
Americans found a 1.5-fold increased risk of venous throm-
bosis for fibrinogen levels above 5 g/L [16].
Since smoking is still common worldwide [17] it is impor-
tant to address the contradictory study results and assess
whether smoking affects the risk of venous thrombosis. In
addition, the multicausal nature of venous thrombosis
makes it important to investigate the effect of smoking in
the presence of other risk factors. For arterial disease,
smoking has been shown to act synergistically with oral
contraceptive use [18]. Therefore we assessed the joint
effect of smoking and oral contraceptive use on the risk of
venous thrombosis. Factor V Leiden and the prothrombin
mutation are the two most frequent prothrombotic muta-
tions and are therefore good candidates to investigate
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gene-environment interaction. To investigate the risk of ve-
nous thrombosis because of smoking, the possible role of
fibrinogen in this relationship and the combination of smok-
ing with oral contraceptive use, factor V Leiden and the
prothrombin 20210A mutation, we performed a large popu-
lation-based case–control study.
Results
In these analyses data on 3,989 patients and 4,900 con-
trol subjects were included. Mean age of patients was 47.5
(5th–95th percentiles, 25.3–67.4) and of control subjects
46.0 (5th–95th percentiles, 25.1–66.2) years old. Fifty-five
percent (n 5 2,185) of patients and 53% (n 5 2,606) of
control subjects were women. In the patient group 58%
(n 5 2,305) was diagnosed with deep venous thrombosis
of the leg, 29% (n 5 1,168) with pulmonary embolism and
13% (n 5 516) with the combination.
In Table I relative risks of venous thrombosis with smok-
ing status are presented. Among patients 37% was current
and 28% was former smoker, in the control subjects 32%
was current and 28% was former smoker. Current and for-
mer smoking were both associated with a moderately
increased risk of venous thrombosis compared with never
smoking (ORcurrent 1.43, CI95 1.28–1.60, ORformer 1.23,
CI95 1.09–1.38). The table presents the pooled odds ratios
with both control groups. The effects contrasting the
patients to each control group separately did not materially
differ from the pooled results (current smoking, partner con-
trols OR 1.20, CI95 1.01–1.44; current smoking, RDD con-
trols OR 1.52, CI95 1.34–1.71; former smoking, partner
controls OR 1.33, CI95 1.13–1.56; former smoking, RDD
controls OR 1.17, CI95 1.03–1.33). To investigate causal
mechanisms we adjusted the associations for fibrinogen
levels. We found slightly attenuated risk estimates after
adjustment (Table I). Adjustment for fibrinogen in the analy-
ses comparing consistent current smokers (at the index
date and time of blood draw) to consistent nonsmokers,
resulted in only slightly lower risk estimates than before
adjustment (ORcurrent 1.46, CI95 1.25–1.71; ORcurrent,adj
1.41, CI95 1.20–1.65).
For pulmonary embolism and deep venous thrombosis,
current smoking resulted in the same relative risk (ORPE
1.53, CI95 1.29–1.80; ORDVT 1.50, CI95 1.31–1.71). For-
mer smoking was associated with a higher relative risk of
pulmonary embolism (OR 1.38, CI95 1.15–1.64) than
of deep venous thrombosis (OR 1.18, CI95 1.02–1.36)
(Table II). Also, smoking increased the risk of thrombosis
more in women than men.
In Table III relative risks are presented for the number of
cigarettes smoked per day and the number of smoking-
years. In current smokers, daily amount smoked was
associated with the risk of venous thrombosis in a dose-
dependent manner. Smoking 20 or more cigarettes per day
resulted in a 1.6-fold increased risk among current smokers
compared with never smokers (OR 1.64, CI95 1.41–1.90).
No dose response relation was found for the number of
smoking-years in either current or former smokers.
Table IV shows the effects of the number of pack-years
for three age categories in current smokers. In the young-
est age category the risk of thrombosis increased with
pack-years smoked, with a 4.3-fold increased risk for smok-
ers with 20 or more pack-years (OR 4.30, CI95 2.59–7.14).
In those aged over 38, we saw no association between
pack-years and the risk of venous thrombosis.
We also investigated the joint effect of smoking with oral
contraceptive use in women aged 18–39 years (Table V).
Among nonusers, smoking was associated with a 2.0-fold
increased risk. Women who used oral contraceptives and
did not smoke had a 3.9-fold increased risk, while those
who also smoked had an 8.8-fold increased risk (compared
with never smokers not using oral contraceptives).
Among noncarriers of factor V Leiden current smoking
resulted in a 1.4-fold increased risk. The joint effect of factor V
Leiden and current smoking resulted in a 5.0-fold increased
risk compared with never smokers without the mutation (Table
VI). For current smokers with the prothrombin 20210A muta-
tion the risk of venous thrombosis increased 6.0-fold com-
pared with never smokerswithout the mutation.
Discussion
In this large population-based case–control study smok-
ing was associated with a moderately increased risk of
TABLE I. Relative Risk of Venous Thrombosis by Smoking Status
Smoking status Patients Partners RDD ORCombined
a (CI95) ORCombined
b (CI95) ORCombined
c (CI95)
Never 1,391 867 1,109 1 1 1
Former 1,136 665 692 1.23 (1.09–1.38) 1.20 (1.03–1.41) 1.22 (1.04–1.43)
Current 1,462 756 811 1.43 (1.28–1.60) 1.40 (1.19–1.63) 1.34 (1.15–1.57)
RDD, random digit dialing controls; OR, odds ratio; CI, confidence interval.
aAdjusted for age, sex, BMI, and pregnancy.
bAdjusted for age, sex, BMI, and pregnancy in participants with measured fibrinogen levels (53% of patients, 50% of control subjects).
cAdjusted for age, sex, BMI, pregnancy and fibrinogen levels in participants with measured fibrinogen levels.
TABLE II. Relative Risk of Venous Thrombosis by Smoking Status
in Different Subgroups
Patients Control subjects ORa(CI95)
DVT
Never 802 1,976 1
Former 642 1,357 1.18 (1.02–1.36)
Current 861 1,567 1.50 (1.31–1.71)
PE
Never 391 1,976 1
Former 349 1,357 1.38 (1.15–1.64)
Current 428 1,567 1.53 (1.29–1.80)
DVT 1 PE
Never 198 1,976 1
Former 145 1,357 0.99 (0.78–1.27)
Current 173 1,567 1.21 (0.96–1.53)
All VTwomen
b
Never 877 706 1
Former 516 334 1.22 (1.02–1.46)
Current 792 443 1.55 (1.33–1.82)
All VTmen
b
Never 514 403 1
Former 618 358 1.03 (0.85–1.26)
Current 669 368 1.42 (1.18–1.71)
DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ra-
tio; CI, confidence interval.
aAdjusted for age, sex, BMI, and pregnancy.
bThree patients were not included in these analyses because two were
transsexuals and one had Klinefelter syndrome, this analysis is per-
formed using the random control subjects only.
98 American Journal of Hematology DOI 10.1002/ajh
venous thrombosis, in current and former smokers. In cur-
rent smokers, who had the highest risk, the risk increased
with the amount of smoking. This is in accordance with the
results of two follow-up studies, ‘‘The Nurses Health Study’’
and ‘‘The study of Men born in 1913’’ [10,11]. These stud-
ies, as well as those that did not found an association
[12,13], all included less than 700 patients with venous
thrombosis, while ours included almost 4,000 patients.
We assessed the number of years someone had
smoked, and found no association with thrombotic risk. It
seems that the effect of smoking on venous thrombosis is
largely an acute effect. This is illustrated by the presence
of a dose response relationship between the amount of
smoking and thrombotic risk in current smokers. Further-
more this is supported by the absence of a dose response
relationship for smoking duration, the higher risk estimates
in current compared with former smokers and the finding of
a dose response relationship with pack-years in young indi-
viduals only.
In our study, the risk estimates in the current smoking
category may be somewhat underestimated, because we
included persons who quit smoking up to one year before
the index date in the current smoking group. In case people
underreported the amount of smoking some nondifferential
misclassification may also have occurred.
Former smoking resulted in a more pronounced risk of
pulmonary embolism than of deep venous thrombosis of
the leg. This finding may reflect local inflammatory effects
in the lungs. The effect of smoking was also more pro-
nounced in women than men. An explanation is our finding
of a synergistic effect of smoking with oral contraceptive
use, which is in accordance with the results of studies on
myocardial infarction [18]. An evaluation of the effects of
oral contraceptives on coagulation in smokers compared
with nonsmokers showed that changes in coagulation in
women taking oral contraceptives were mainly evident in
smoking women [19].
To investigate a mechanism for the association between
smoking and venous thrombosis we adjusted our analyses
TABLE III. Relative Risk of Venous Thrombosis by Number of
Cigarettes Smoked Per Day and Smoking Period
Smoking amount
(cigarettes/day) Patients
Control
subjects ORa (CI95)
Current
Never 1,391 1,696 1
1–9 242 277 1.23 (1.00–1.50)
10–19 524 528 1.41 (1.21–1.64)
20 676 589 1.64 (1.41–1.90)
Former
Never 1,391 1,781 1
1–9 286 321 1.20 (1.00–1.45)
10–19 372 400 1.22 (1.03–1.45)
20 444 474 1.08 (0.92–1.28)
Smoking period (years)
Current
Never 1,391 1,689 1
1–9 162 166 1.54 (1.19–2.01)
10–19 279 324 1.37 (1.13–1.67)
20 935 834 1.46 (1.27–1.67)
Former
Never 1,391 1,748 1
1–9 226 243 1.33 (1.08–1.64)
10–19 325 382 1.09 (0.91–1.31)
20 425 420 1.11 (0.93–1.32)
OR, odds ratio; CI, confidence interval.
aAdjusted for age, sex, BMI, and pregnancy.
TABLE IV. Relative Risk of Venous Thrombosis by Number of
Pack-Years in Three Age Categories (Tertiles) in Current Smokers
Pack-years
ORa (CI95) ORa (CI95) ORa (CI95)
<37.8 37.8–51.1 51.1
Never 1 1 1
1–9 1.38 (1.07–1.77) 0.94 (0.66–1.36) 1.25 (0.76–2.07)
10–19 2.76 (1.99–3.83) 1.32 (0.97–1.79) 1.06 (0.71–1.59)
20 4.30 (2.59–7.14) 1.34 (1.05–1.72) 1.14 (0.91–1.42)
OR, odds ratio; CI, confidence interval.
Note: The pack-year analyses were performed in three different age
categories because the number of pack-years was dependent on the
age of the participants. We established the categories by dividing the
age distribution of the current smokers into tertiles.
aAdjusted for age, sex, BMI, and pregnancy.
TABLE V. Combined Effect of Smoking Status With Oral
Contraceptive (OC) Use on the Risk of Venous Thrombosis
in Women Aged 18–39
Smoking
status
OC
use Patients
Control
subjects ORa (CI95)
Never no 105 168 1
Former no 54 52 1.63 (1.00–2.67)
Current no 87 93 2.03 (1.33–3.11)
Never yes 257 189 3.90 (2.63–5.79)
Former yes 82 40 4.83 (2.89–8.08)
Current yes 271 94 8.79 (5.73–13.49)
OR, odds ratio; CI, confidence interval.
Note: The OC analyses were performed with random control subjects
only.
aAdjusted for age, BMI, and pregnancy.
TABLE VI. Combined Effect of Smoking Status With Factor V
Leiden (FVL) and the Prothrombin (FII) 20210A Mutation on
the Risk of Venous Thrombosis
Smoking status FVL Patients Control subjects ORa (CI95)
Never no 1,085 1,375 1
Former no 930 1,017 1.21 (1.06–1.39)
Current no 1,106 1,048 1.43 (1.26–1.63)
Never yes 234 70 3.41 (2.53–4.58)
Former yes 161 41 3.76 (2.58–5.49)
Current yes 223 42 5.05 (3.46–7.38)
FII 20210A Patients Control subjects ORa (CI95)
Never no 1,238 1,517 1
Former no 1,039 1,111 1.21 (1.06–1.37)
Current no 1,269 1,168 1.41 (1.25–1.60)
Never yes 81 16 3.17 (1.94–5.18)
Former yes 52 11 3.01 (1.60–5.68)
Current yes 60 5 6.06 (2.67–13.76)
OR, odds ratio; CI, confidence interval.
Note: the inclusion of matched case control pairs in the analyses was
dependent on the category (BMI, FVL; BMI, FII) of both individuals.
aAdjusted for age, sex, BMI, and pregnancy.
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for fibrinogen levels, hypothesizing that the risk was medi-
ated via elevated fibrinogen levels. This adjustment, how-
ever, resulted only in slightly decreased risk estimates for
current smoking, and therefore fibrinogen levels are not a
crucial part of the mechanism. The question remains which
other factors affected by smoking lead to the increased risk
of venous thrombosis. A study that investigated the effect
of smoking on the coagulation system found increased lev-
els of factor VII, prothrombin, factor XI peptide, and factor
X peptide in smokers [8]. Besides coagulation factors,
inflammatory factors may be involved. Interleukine-6 has
been shown to be elevated in smokers [4] and is also asso-
ciated with the risk of recurrent venous thrombosis [20].
Control subjects were drawn from two different sources.
There were only minor differences when estimates were
obtained with each control group separately. These differ-
ences are likely to be chance variations, although minor
true differences cannot be ruled out, possibly related to dif-
ferences in nonresponse.
In conclusion, in this large population-based case–control
study we found smoking to be a moderate risk factor for ve-
nous thrombosis, which acts synergistically with oral contra-
ceptive use. The joint effect of smoking with the factor V
Leiden mutation or the prothrombin 20210A mutation was
also slightly higher than the sum of the separate effects.
Our findings suggest that fibrinogen levels are not an im-
portant mediator of the effect of smoking on the risk of ve-
nous thrombosis.
Methods
Study design
In the Multiple Environmental and Genetic Assessment of risk factors
for venous thrombosis (MEGA study), we included consecutive patients
with a first diagnosis of venous thrombosis between March 1999 and
September 2004. Patients were selected from the files of the Anticoa-
gulation Clinics in Amsterdam, Amersfoort, The Hague, Leiden, Rotter-
dam, and Utrecht. In the Netherlands, Anticoagulation Clinics monitor
anticoagulation treatment in all patients in a geographically well-defined
area. Patients between the age of 18 and 70 with deep venous throm-
bosis of the leg, pulmonary embolism or a combination of these diag-
noses were included. The diagnostic methods were verified in a
random sample of the overall patient group (n 5 742). Within this
group the diagnosis of 97% of deep venous thrombosis and 78% of
pulmonary embolism had been objectively confirmed. The tests
included compression ultrasonography, Doppler ultrasound, impedance
plethysmography, and contrastvenography for the diagnosis of deep
venous thrombosis and perfusion and ventilation lung scanning, spiral
computer tomography and pulmonary angiography for pulmonary
embolism.
Patients with severe psychiatric problems or those unable to speak
Dutch were considered as ineligible. Of the 6,331 eligible patients, 276
died soon after the venous thrombosis. Of the remaining 6,055 patients
5,051 participated (83%). Of the nonparticipants 82 persons were in
the end stage of disease and 922 refused to participate or could not be
located. Of the participants, 4,637 (77%) patients returned the ques-
tionnaire. Participants who did not return a questionnaire completed a
short questionnaire by phone, which did not include questions on
smoking habits.
Partners of patients were asked to volunteer as control subjects. Of
the 5,051 participating patients, 3,657 had an eligible partner. One part-
ner died soon after the request for participation. Of the remaining 3,656
partners, 2,982 participated (82%). Of the nonparticipants 18 were in
end-stage disease, 649 refused to participate or could not be located
and for seven persons the reason for nonparticipation was unknown. A
questionnaire was returned by 2,821 participating partners (77%).
From January 2002 until September 2004, additional control subjects
were recruited by random digit dialing (RDD) [21]. Phone numbers
were dialed at random within the geographical inclusion area of the
patients. The random controls were frequency matched to the patients
with respect to age and sex. Only control subjects between the age of
18 and 70 years with no history of deep venous thrombosis were
included and the same exclusion criteria were applied as for the
patients.
Of the 4,350 eligible random control subject, four died before they
were able to participate. Of the remaining 4,346 persons 3,000 partici-
pated (69%). Of the nonparticipants 15 were in the end stage of dis-
ease and 1,331 refused to participate or could not be located. A ques-
tionnaire was returned by 2,789 participating random control subjects
(64%).
All participants gave written informed consent. The study was
approved by the Medical Ethics Committee of the Leiden University
Medical Center, Leiden, The Netherlands.
Data collection
Within a few weeks after diagnosis and registration at the anticoagu-
lation clinics patients received a letter with information about the study
and were subsequently contacted by phone. Both patient and control
subjects received the questionnaire shortly after inclusion. The ques-
tionnaires included items on smoking habits, body weight and body
height, malignancies, pregnancies, and use of oral contraceptives.
Most questions referred to a period of 12 months prior to the index
date, i.e., the date of diagnosis of the thrombosis of the patient for
patients and partners and the date of filling in the questionnaire for the
random control subjects.
When someone reported to smoke one cigarette per month or more
the person was considered a smoker. Smokers were asked to report
the age at which they started smoking, the age they quitted smoking, if
there was a period in-between they did not smoke and the (cumulative)
duration of such periods. Smokers were divided in current, former, and
never smokers. When the difference between the age at index date
and the age of smoking cessation was 1 year or less, the person was
considered a current smoker. The average number of cigarettes, self-
rolled cigarettes, cigars or pipes smoked per day was also asked for.
Because only a minor difference was found between different types of
smoking and their risk of venous thrombosis, cigar and pipe smoking
were included in the analysis by arbitrarily counting 1 cigar as 3 ciga-
rettes and 1 pipeful as 2½ cigarettes. Several individuals wrote down
the number of packages instead of the number of cigarettes smoked.
In this case, the number of cigarettes was calculated with one package
counted as 20 cigarettes. For smokers of self-rolled cigarettes one
package was counted as 50 cigarettes. Pack-years were defined as the
average number of cigarettes per day divided by 20 and multiplied by
the number of smoking years.
Individuals with malignancies diagnosed within 10 years before the
index date (active malignancies) were excluded from all analyses. In
addition, participants with missing data regarding items of the smoking
questions, body weight and height or pregnancy were excluded from
the analyses. In the analyses only partner controls with a participating
patient were included, leading to a total of 3,989 patients, 2,288, part-
ner and 2,612 random control subjects in the present analyses.
Blood collection
At least three months after withdrawal of anticoagulation the patients
and their partners were asked to visit the anticoagulation clinic after an
overnight fast and a blood sample was drawn. Only in case of continu-
ous use for more than one year a blood sample was taken during anti-
coagulation therapy. From December 1999 onwards, we obtained self-
administered buccal swabs by mail when participants were unable or
unwilling to come for a blood draw. From June 2002 onwards, blood
draws were no longer performed in patients and their partners, and the
study was restricted to DNA collection by buccal swabs sent by mail.
The random controls were invited for a blood draw within a few weeks
after the questionnaire was sent. Within this group buccal swabs were
sent when someone refused the blood draw. During the blood draws in-
formation on smoking habits after the index date was obtained. In case
of DNA collection by mailed buccal swabs a short interview was per-
formed by phone.
Within the patient group 3,745 provided a blood sample or buccal
swab (94%). In the control subjects 4,004 blood samples or buccal
swabs were obtained (82%). Genotyping was successful in 3,739
patients and 3,983 control subjects for factor V Leiden and in 3,739
patients and 3,984 control subjects for the prothrombin 20210A mutation
[22]. Fibrinogen levels were successfully determined in all blood samples,
consisting of 2,118 patient and 2,485 control samples. Fibrinogen activity
was measured according to the method of Clauss [23]. Calibration was
performed using STA preciclot plus I and II. The intra-assay coefficient of
variation (CV) was 1.81, the inter-assay CV was 3.78.
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Statistical analysis
As estimates of relative risks we calculated odds ratios (ORs) and
95% confidence intervals (CI95) according to the method of Woolf [24].
With a multiple logistic regression model ORs were adjusted for age
(continuous), sex (categorical), body mass index (BMI 5 kg/m2) (con-
tinuous) and pregnancy (categorical). Adjustment for age (10 catego-
ries) and body mass index (8 categories) as categorical variables
resulted in approximately the same risk estimates. In the analyses with
partners as the control group, we performed a matched analysis to
adjust for similar life style factors between patients and their partners
(2,288 pairs) [25]. In the analyses with the random control subjects an
unmatched analysis including all patients and random control subjects
was performed. Because the results of the matched and unmatched
analyses showed consistently elevated relative risks in all the analyses,
we calculated pooled risk estimates with a method that combines the
matched and unmatched analyses (see Appendix). This analysis takes
into account the presence of 2,288 patients in both the matched and
unmatched analyses. When analyzing the risk in men and women sep-
arately it was not possible to perform a matched analysis with the part-
ner controls, as control individuals were nearly always of the opposite
sex. Therefore, risk estimates were calculated with an unmatched anal-
ysis with all patients and the random control subjects.
In the analyses adjusted for fibrinogen levels (categorical), individuals
who quitted smoking after the index date but before the blood draw
were included in the former smoking category. Individuals who started
smoking in the period between the index date and the blood draw were
included as current smokers. To further remove any effect of starters
and quitters, we restricted an analysis adjusted for fibrinogen levels to
individuals who consistently either smoked or did not smoke at the
index date and the time of the blood draw. SAS 9.1 (SAS institute,
Cary, NC) was used for all statistical analyses.
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Appendix: Combining the Estimates of the Conditional
and Unconditional Logistic Regression
Combining two estimates of the odds ratio
In our approach the two estimates of the log-odds ratio
are combined into one overall log-odds ratio. Since both
estimates use the same subset of cases, the estimates are
correlated. The correlation between the two estimates is
estimated using a sandwich estimator, which is the com-
monly used estimator in statistics [26]. Details about this
calculation are given later on in this appendix. The correla-
tion is used to combine the two estimates in the most effi-
cient way and to calculate the correct standard errors.
We consider first the case when there is only one param-
eter to combine. Let b^1 and b^2 be the estimated log odds
ratios in the two different analyses with respective standard
errors s1 and s2 and let q^ be the estimated correlation
coefficient between the two estimates. In this case the
combined estimate is a weighted mean of b^1 and
b^2 : b^com ¼ w b^1 þ ð1 wÞb^2 with standard error scom ¼
seðb^comÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
w2s21 þ ð1 wÞ2s22 þ 2wð1 wÞqs1s2
q
: It is
straightforward to show that the optimal weight is given by
the following equation w ¼ ðs22  q^s1s2Þ=ðs21 þ s22  2q^s1s2Þ:
In general, there are two multidimensional parameters
u1 ¼ ða1;bÞ and u2 ¼ ða2;bÞ; respectively. The k-dimen-
sional b-parameter is the shared part. The parameters a1
and a2 of dimension k1 and k2 , respectively, are not
shared, for example because of different confounding varia-
bles in the two analyses, or because the effect of a con-
founder is expected to act differently in the two models.
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Suppose that b^1 and b^2 are the two correlated estimates
of the shared part b with covariance matrices covðb^1Þ ¼
C1, covðb^2Þ ¼ C2; and covðb^1; b^2Þ ¼ C12
Then the most efficient estimate of b (the weighted least
square estimate) is given by
b^com ¼
Ik
Ik
 T C1 C12
C21 C2
 1 Ik
Ik
  !1
3
Ik
Ik
 T C1 C12
C21 C2
 1
b^1
b^1
 !
with covariance matrix
covðb^comÞ ¼ IkIk
 T
C1 C12
C21 C2
 1
Ik
Ik
  !1
:
Here Ik is the k-dimensional identity matrix.
Estimation of the correlation between the two
estimated odds ratios
In the general situation, there are two multidimensional
parameters y1 5 (a1,b) and y2 5 (a2,b), respectively.
Assume that both parameters are estimated by multiple
regression models (in our situation y1 is estimated by con-
ditional logistic regression and y2 by unconditional logistic
regression.) When fitting this models by maximum likeli-
hood we obtain the estimated parameters u^1 ¼ ða^1; b^1Þ and
u^2 ¼ ða^2; b^2Þ; the Fisher-information matrices I1 and I2 and
the score matrices U1 and U2, where, generally I ¼ @2 l@u2
and Uij ¼ @li ðu^Þ@uj is the derivative of the log-likelihood contribu-
tion of individual i with respect to parameter yj.
Because of the overlap the estimated parameters
u^1 ¼ ða^1; b^1Þ and u^2 ¼ ða^2; b^2Þ are dependent. Their covari-
ance matrix can be estimated by a sandwich estimator:
covðu^1; u^2Þ ¼ I11 U1;overlapTU2;overlapI12 using only the rows of
U1 and U2 that correspond to the overlapping observations.
From the estimated covariance matrix covðu^1; u^2Þ we can
obtain the covariance matrix of the common part
covðb^1; b^2Þ:
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